She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient population is heterogenous in how they are affected by the disease. Plus, a description of Epicrispr's epigenome approach to science, and her personal relationship to facioscapulohumeral muscular dystrophy.
View all episodes
By BiotechTV
4.3
66 ratings
She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient population is heterogenous in how they are affected by the disease. Plus, a description of Epicrispr's epigenome approach to science, and her personal relationship to facioscapulohumeral muscular dystrophy.
3,222 Listeners
1,910 Listeners
124 Listeners
324 Listeners
61 Listeners
9,957 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
512 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners